Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,246 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Measuring the preferences of injectable opioid agonist treatment (iOAT) clients: Development of a person-centered scale (best-worst scaling).
Dobischok S, Metcalfe R, Matzinger E, Palis H, Marchand K, Harrison S, MacDonald S, Byres D, Schechter M, Bansback N, Oviedo-Joekes E. Dobischok S, et al. Among authors: macdonald s. Int J Drug Policy. 2023 Feb;112:103948. doi: 10.1016/j.drugpo.2022.103948. Epub 2022 Dec 29. Int J Drug Policy. 2023. PMID: 36586152 Review.
Differential effect of cannabis use on opioid agonist treatment outcomes: Exploratory analyses from the OPTIMA study.
Elkrief L, Bastien G, McAnulty C, Bakouni H, Hébert FO, Socias ME, Le Foll B, Lim R, Ledjiar O, Marsan S, Brissette S, Jutras-Aswad D; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse. Elkrief L, et al. J Subst Use Addict Treat. 2023 Jun;149:209031. doi: 10.1016/j.josat.2023.209031. Epub 2023 Mar 30. J Subst Use Addict Treat. 2023. PMID: 37003540 Free article. Clinical Trial.
Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic review.
Adams A, Blawatt S, MacDonald S, Finnick R, Lajeunesse J, Harrison S, Byres D, Schechter MT, Oviedo-Joekes E. Adams A, et al. Among authors: macdonald s. Int J Drug Policy. 2023 Jul;117:104058. doi: 10.1016/j.drugpo.2023.104058. Epub 2023 May 8. Int J Drug Policy. 2023. PMID: 37182352 Free PMC article. Review.
Clients' experiences on North America's first take-home injectable opioid agonist treatment (iOAT) program: a qualitative study.
Oviedo-Joekes E, Dobischok S, Carvajal J, MacDonald S, McDermid C, Klakowicz P, Harrison S, LaJeunesse J, Chow N, Brown M, Gill S, Schechter M. Oviedo-Joekes E, et al. Among authors: macdonald s. BMC Health Serv Res. 2023 May 26;23(1):553. doi: 10.1186/s12913-023-09558-6. BMC Health Serv Res. 2023. PMID: 37237256 Free PMC article.
The impact of relaxing restrictions on take-home doses during the COVID-19 pandemic on program effectiveness and client experiences in opioid agonist treatment: a mixed methods systematic review.
Adams A, Blawatt S, Magel T, MacDonald S, Lajeunesse J, Harrison S, Byres D, Schechter MT, Oviedo-Joekes E. Adams A, et al. Among authors: macdonald s. Subst Abuse Treat Prev Policy. 2023 Sep 30;18(1):56. doi: 10.1186/s13011-023-00564-9. Subst Abuse Treat Prev Policy. 2023. PMID: 37777766 Free PMC article. Review.
2,246 results